FUJIREBIO-EUROPE
30.3.2022 08:02:15 CEST | Business Wire | Press release
H.U. Group Holdings Inc. and its wholly-owned subsidiary Fujirebio today announced the availability of the Lumipulse G β-Amyloid 1-42 Plasma and Lumipulse G β-Amyloid 1-40 Plasma assays for the fully automated LUMIPULSE G immunoassay systems. These CLEIA (chemiluminescent enzyme immunoassay) assays allow for the quantitative measurement of β-amyloid1-42 and β-amyloid1-40 in human plasma within just 35 minutes.
“With the launch of these two new tests on our robust LUMIPULSE G platform, Fujirebio truly becomes an essential actor in the field of blood-based testing,” said Goki Ishikawa, President and CEO of Fujirebio Holdings, Inc. “Our cerebrospinal fluid-based neurodegeneration IVD tests are already used by laboratories for routine testing in many countries across the world for decades, and this release continues the new chapter that we started writing earlier this month, with the launch of the Lumipulse G pTau 181 Plasma.”
The two new automated blood-based biomarker assays are available for Research Use Only. They will allow researchers and clinical research professionals across the world to further study the clinical utility of the Aβ1-42 , Aβ1-40 and the pTau 181 markers in Alzheimer’s disease and related disorders on the LUMIPULSE G platform. This platform has the required throughput and meets the regulatory requirements to support possible future routine use of blood-based testing of these markers.
The Lumipulse G β-Amyloid 1-42 Plasma and the Lumipulse G β-Amyloid 1-40 Plasma assays, together with the already available Lumipulse G pTau 181 Plasma assay, complement the panel of four key cerebrospinal fluid (CSF) assays (Aβ1-42 , Aβ1-40 , tTau and pTau 181) already available within the Lumipulse G as well as the INNOTEST® Neuro product portfolio. These four CSF parameters can provide essential information on the presence of amyloid and tau pathology in neurodegenerative disease.
There is hope that blood-based testing can become an even simpler, more accessible, and more scalable approach to help support the diagnosis of Alzheimer’s disease. Current research indicates that the plasma β-amyloid1-42 /β-amyloid1-40 ratio has the potential to be used in clinical settings and within clinical trials to predict brain β-amyloid burden.1-2 It could also be used as a tool to evaluate target engagement and efficacy of disease-modifying drugs.3
The development of the Lumipulse G β-Amyloid 1-42 Plasma and Lumipulse G β-Amyloid 1-40 Plasma assays has been supported by the Flanders Innovation & Entrepreneurship (VLAIO).
About Fujirebio
Fujirebio, a member of H.U. Group Holdings Inc., is a global leader in the field of high-quality in vitro diagnostics (IVD) testing. It has more than 50 years’ accumulated experience in the conception, development, production and worldwide commercialization of robust IVD products.
Fujirebio was the first company to develop and market CSF biomarkers under the Innogenetics brand over 25 years ago. Fujirebio remains the only company with such a comprehensive line-up of manual and fully automated AD assays and consistently partners with organizations and clinical experts across the world to develop new pathways for earlier, easier and more complete neurodegenerative diagnostic tools. More information can be found at www.fujirebio.com/alzheimer .
References:
1. Palmqvist S, et al
. EMBO Mol Med, 11(12): e11170, 2019
.
2. Nakamura A, et al
. Nature, 554(7691): 249-254, 2018
.
3. Teunissen C, et al.
Lancet Neurol, 21(1): 66-77, 2022
.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220329005882/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Impartner Releases AI Ecosystem Playbook to Help Organizations Move from AI Experimentation to Execution1.10.2026 15:00:00 CEST | Press release
The AI Ecosystem Playbook provides a practical framework for assessing AI readiness, identifying high-value opportunities, addressing foundational gaps, and building a roadmap for AI adoption. Impartner, the world’s leading partner revenue orchestration platform, today announced the release of its AI Ecosystem Playbook, a new resource designed to help leaders and teams assess their current AI capabilities, identify areas where AI can support business goals, and develop a practical path to implementation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001661549/en/ Impartner’s AI Ecosystem Playbook helps organizations assess AI readiness and identify opportunities to apply AI across PRM 3.0, partner revenue orchestration, and the partner lifecycle. As AI moves from experimentation into everyday operations, companies need more than a collection of potential applications. They need a framework for understanding where they ar
Whiteford Adds Six Partners in New York City, Expanding its Litigation, International and Corporate Practices1.10.2026 15:00:00 CEST | Press release
Lateral group joins growing Midtown Manhattan office as firm pursues targeted expansion strategy Whiteford, Taylor & Preston, a full-service law firm with offices across the East Coast, today announced that six partners from Chambers-rated Lazare Potter Glazer & Moyle LLP have joined Whiteford’s New York office: David E. Potter, James F. Moyle, Johannes K. Gäbel, Jaipat Singh Jain, Anna Pia D. Felix and Jacob Englander. This team expands Whiteford's New York office to more than two dozen attorneys and deepens the firm's commercial and securities litigation, employment, cross-border and corporate capabilities in the New York market. The six partners bring decades of combined experience representing mid-market companies, investment advisers, hedge funds, foreign corporations, entrepreneurs and executives in litigation, regulatory investigations, and complex business transactions. "We are expanding with our clients, our markets and our reputation," said Martin Fletcher, Whiteford's Managi
Skechers Enters Super Shoe Era With Innovative Skechers AERO Elite1.10.2026 14:20:00 CEST | Press release
Groundbreaking Design Gives Elite Runners the Performance to Break Barriers and Records in Any Race Skechers is redefining what it means to run fast with the Skechers AERO Elite. The latest addition to the innovative Skechers AERO Series makes its global racing debut today—marking a landmark moment as the performance brand’s first super shoe. Engineered to perform from 5Ks to marathons, the design minimizes weight and maximizes responsiveness, all while delivering Skechers’ signature comfort. The AERO Elite is built to win with the performance runners at any level need to go further, faster, and achieve that next personal record. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261001865320/en/ Introducing the Skechers AERO Elite, the brand’s first super shoe designed for racing. “The Skechers AERO Elite is the culmination of years of elite-level running innovation—our most technically advanced running shoe to date and a direc
Visa Data Shows Stablecoins Gaining Traction in Business Payments1.10.2026 14:00:00 CEST | Press release
New Visa data shows nearly 17%1 of stablecoin-linked card volume is occurring across business and commercial card programs, underscoring growing adoption of stablecoins for settlement, treasury management and cross-border commerce. Today, Visa (NYSE: V) shared new data showing the growing adoption of stablecoins across business payments and commercial card programs, underscoring how stablecoins are increasingly being used as financial infrastructure. The findings come as businesses, financial institutions and payment providers increasingly explore stablecoins for settlement, treasury management, payouts and cross-border commerce. New Visa data shows: Approximately 17% of stablecoin-linked card volume in FY26 year-to-date occurred across business and commercial card programs. Visa today supports more than 160 stablecoin-linked card programs spanning consumer, business and commercial card activity. Payments volume across these programs has grown nearly 200% year over year. Businesses are
Moody’s Analytics and Allvue Launch Credit Risk Model to Identify Early Signs of Borrower Stress in Private Credit1.10.2026 14:00:00 CEST | Press release
Moody’s Analytics EDF-X Private Credit Model, powered by Allvue data, gives investors and lenders an earlier view of borrower stress in a rapidly growing market Moody’s Corporation (NYSE: MCO), a global leader in risk assessment and credit analytics, and Allvue Systems, LLC, a leading technology and data provider for private capital markets, today announced the launch of the Moody’s Analytics EDF-X Private Credit Model, a new forward-looking credit risk model purpose-built for the private credit market. Built on Moody’s deep credit expertise and Allvue’s private credit performance data, the model identifies early signals of borrower stress, such as covenant waivers and payment-in-kind arrangements, well before they show up as missed payments or defaults. Moody’s projects private credit to approach $4 trillion in assets by 2030, and investors and lenders are increasingly seeking earlier visibility on where risk is building across portfolios. Unlike public credit markets where participan
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom